With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.55687-02-0,6-Bromo-2-chloroquinoxaline,as a common compound, the synthetic route is as follows.
55687-02-0, To a stirred suspension of (2-[(2S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl]-1-{[2 (trimethylsilyl) ethoxy]methyl}- 1 H-imidazol-5-yl)boronic acid (150 mg, 0.26 mmol), obtained from Preparation 13b, in 1 ,2-dimethoxyethane (1 mL), was added 6-bromo-2-chloroquinoxaline (62 mg, 0.26 mmol), obtained from Preparation 30,Pd(dppf)CI2.DCM (13 mg, 0.05mmol) and 2M Na2CO3 (aq) (0.38 mL, 0.77 mmol). The mixture was degassed, then put under nitrogen three times and then stirred at 300C for 3 hours. The resulting dark brown mixture was partitioned between ethyl acetate (5 mL) and water (5 mL). The organic phases were extracted and the aqueous phase was washed with more EtOAc (5 mL). The organic phases were combined, dried (Na2SO4), filtered and concentrated in vacuo. The resulting crude material was purified by column chromatography (dry loaded redisep (4 g), 20 to 80 % ethyl acetate, heptane) to give 98 mg of the title compound as a orange foam.1H-NMR (400 MHz, MeOD): delta= 9.28 (1 H, d), 8.22 (1 H, d), 7.95 (3H, m), 6.70 (1 H, m), 5.95 (1 H, dd), 5.16(1 H, m), 3.75-3.52 (4H, m), 2.42 (1 H, m), 2.24-1.91 (3H, m), 1.46-1.21 (9H, m), 0.86 (2H, m), -0.17 (9H, d).LCMS (run time = 6 min): Rt = 4.38 min; m/z 574; 576 [M+H]+
As the paragraph descriping shows that 55687-02-0 is playing an increasingly important role.
Reference£º
Patent; PFIZER LIMITED; MILBANK, Jared Bruce John; PRYDE, David Cameron; TRAN, Thien Duc; WO2011/4276; (2011); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider